功能MRI在食管癌分期及放化疗中的应用研究

doi:10.3760/cma.j.issn.1004-4221.2014.05.025

摘要
图/表
参考文献()
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要食管癌是世界第8大恶性肿瘤,且发病率在迅速增长^[1]。准确的术前分期、精确的靶区勾画和及时的疗效评估,在判断食管癌患者预后及制定个体化治疗决策中具有重要意义。MRI是一种无辐射、无创伤的检查手段,早期由于成像速度慢及伪影大等问题,在体部肿瘤中应用价值有限。随着软硬件技术提高,如快速自旋回波序列及快速采集技术的发展,生理门控的使用,超顺磁性氧化铁等新型造影剂的应用,高分辨率三维稳态扰相成像序列、DWI、DCEMRI等功能成像的开发,不但明显缩短了成像时间,而且提高了成像质量。笔者主要概述功能MRI在食管癌分期、放疗靶区勾画、疗效评估及判断预后方面的价值。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	黄一凡
	钱立庭

收稿日期: 2014-01-04

通讯作者: 钱立庭

引用本文:

黄一凡,钱立庭. 功能MRI在食管癌分期及放化疗中的应用研究[J]. 中华放射肿瘤学杂志, 2014, 23(5): 458-460.

$author.xingMing_EN,$author.xingMing_EN. [J]. Chinese Journal of Radiation Oncology, 2014, 23(5): 458-460.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2014.05.025 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2014/V23/I5/458

[1] Siegel R,Naishadham D,Jemal A. Cancer statistics,2012[J].CA Cancer J Clin,2012,62:10-29.
[2] Wu LF,Wang BZ,Feng JL,et al. Preoperative TN staging of esophageal cancer: comparison of miniprobe ultrasonography,spiral CT and MRI[J].World J Gastroenterol,2003,9:219-224.
[3] Sakurada A,Takahara T,Kwee TC,et al. Diagnostic performance of diffusion-weighted magnetic resonance imaging in esophageal cancer[J]. Eur Radiol,2009,19:1461-1469.
[4] Takashima S,Takeuchi N,Shiozaki H,et al. Carcinoma of the esophagus: CT vs MR imaging in determining respectability[J]. Am J Roentgenol,1991,156:297-302.
[5] Petrillo R,Balzarini L,Bidoli P,et al. Esophageal squamous cell carcinoma: MRI evaluation of mediastinum[J]. Gastrointest Radiol,1990,15:275-278.
[6] Riddell AM,Allum WH,Thompson JN,et al. The appearances of oesophageal carcinoma demonstrated on high-resolution,T2-weighted MRI,with histopathological correlation[J].Eur Radiol,2007,17:391-399.
[7] Yamada I,Izumi Y,Kawano T,et al. Esophageal carcinoma: evaluation with high-resolution three-dimensional constructive interference in steady state MR imaging in vitro[J]. J Magn Reson Imaging,2006,24:1326-1332.
[8] Krupski G,Lorenzen J,Gawad K,et al. MRI-based N-staging in esophageal cancer[J].Rofo,2002,174:1269-1273.
[9] Nishimura H,Tanigawa N,Hiramatsu M,et al. Preoperative esophageal cancer staging: magnetic resonance imaging of lymph node with ferumoxtran-10,an ultrasmall superparamagnetic iron oxide[J]. J Am Coll Surg,2006,202:604-611.
[10] Will O,Purkayastha S,Chan C,et al. Diagnostic precision of nanopartic1e-enhanced MRI for lymph-node metastases: a meta-analysis[J].Lancet OncoL,2006,7:52-56.
[11] Choi SH,Moon WK,Hung JH,et al. Lymph node metastasis: ultrasmall superparamagnetic iron oxide-enhanced MR imaging versus PET/CT in a rahbit model[J].Radiology,2007,242:137-143.
[12] Sakurada A,Takahara T,Kwee TC,et al. Diagnostic performance of diffusion-weighted magnetic resonance imaging in esophageal cancer[J]. Eur Radiol,2009,19:1461-1469.
[13] Alper F,Turkyilmaz A,Kurtcan S,et al. Effectiveness of the STIR turbo spin-echo sequence MR imaging in evaluation of lymphadenopathy in esophageal cancer[J].Eur J Radiol,2011,80:625-628.
[14] 康厚艺,张伟国,金榕兵,等.肿瘤MR全身弥散加权成像与PET成像初步对比[J].中国医学影像技术,2010,26:748-751.
[15] 薛鹏,尚英杰,张伟,等.全身类PET成像在恶性肿瘤中的应用[J].实用放射学杂志,2013,29:1158-1163.
[16] Pfannenberg C,Aschoff P,Schanz S,et al. Prospective comparison of ¹⁸F-fluorodeoxylucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma[J]. Eur J Cancer,2007,43:557-564.
[17] Sakurai Y,Kawai H,Iwano S,et al. Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression(DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer[J]. J Med Imaging Radiat Oncol,2013,57:297-305.
[18] Murtz P,Krautmacher C,Trber F,et al. Diffusion-weighted whole-bodyMR imaging with background body signal suppression: a feasibility study at 3.0 Tesla[J].Eur Radiol,2007,17:3031-3037.
[19] Komori T,Narabayashi I,Matsumura K,et al.2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience[J]. Ann Nucl Med,2007,21:209-215.
[20] Stéphane V,Samuel B,Vincent D,et al. Comparison of PET-CT and magnetic resonance diffusion weighted imaging with body suppression(DWIBS) for initial staging of malignant lymphomas[J]. Eur J Radiol,2013,82:2011-2017.
[21] Akay S,Kocaoglu M,Emer O,et al. Diagnostic accuracy of whole-body diffusion-weighted magnetic resonance imaging with 3.0?T in detection of primary and metastatic neoplasms[J]. J Med Imaging Radiat Oncol,2013,57:274-282.
[22] 汪宁,张晓鹏,唐磊,等.食管肿瘤扩散加权成像序列参数优化及相关影像病理对照研究[J].中国医学影像技术,2005,21:1826-1829.
[23] 侯栋梁,时高峰,高献书,等.磁共振弥散加权成像在食管癌大体肿瘤靶区勾画中的应用价值[J].中华放射肿瘤学杂志,2012,21:343-347.
[24] Hou DL,Shi GF,Gao XS,et al. Improved longitudinal length accuracy of gross tumor volume delineation with diffusion weighted magnetic resonance imaging for esophageal squamous cell carcinoma[J].Radiat Oncol,2013,8:169-173.
[25] 刘辉,时高峰,邵娴,等.磁共振弥散加权成像在早期评估食管癌放疗疗效的应用价值[J].河北医药,2013,35:3403-3404.
[26] 田华,王澜,韩春,等.磁共振弥散加权成像在食管癌精确放疗中的应用价值[J].中华放射肿瘤学杂志,2012,21:223-226.
[27] Lagendijk JJ,Raaymakers BW,Raaijmakers AJ,et al.MRI linac integration. Radiother Oncol,2008,86:25-29.
[28] Raaymakers BW,Lagendijk JJ,Overweg J,et al. Integrating a 1.5T MRI scanner with a 6 MV accelerator: proof of concept[J]. Phys Med Biol,2009,54:229-237.
[29] Kerkhof EM,Raaymakers BW,Van der Heide UA,et al. Online MRIguidance for healthy tissue sparing in patients with cervical cancer: an IMRT planning study[J]. Radiother Oncol,2008,88:241-249.
[30] Kamel IR,Reyes DK,Liapi E,et al. Functional MR imaging assessment of tumor response after 90Y mierosphere treatment in patients with unresectable hepatocellular carcinoma[J].J Vasc Interv Radiol,2007,18:49-56.
[31] Sun Y,Cui Y,Tang L,et al. Early evaluation of cancer response by a new functional biomarker: apparent diffusion coefficient[J].Am J Roentgenol,2011,197:23-29.
[32] Aoyagi T,Shuto K,Okazumi S,et al. Apparent diffusion coefficient values measured by diffusion-weighted imaging predict chemoradiotherapeutic effect for advanced esophageal cancer[J]. Dig Surg,2011,28:252-257.
[33] Weber MA,Bender K,Christian C,et al. Assessment of Diffusion-weighted MRI and ¹⁸F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction[J].J Gastrointestin Liver Dis,2013,22:45-52.
[34] Oberholzer K,Pohlmann A,Schreiber W,et al. Assessment of tumor microcirculation with dynamic contrast-enhanced MRI in patients with esophageal cancer: initial experience[J]. J Magn Reson Imaging,2008,27:1296-1301.
[35] Chang EY,Li X,Jerosch M,et al. The evaluation of esophageal adenocarcinoma using dynamic contrast-enhanced magnetic resonance imaging[J]. J Gastrointest Surg,2008,12:166-175.